Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
Want to see ZNTL full AI Analyst Report?
ZNTL Stock Chart & Stats
$1.41
-$0.17(-5.69%)
At close: 4:00 PM EST
$1.41
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.13 - $6.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)716.92K
Market Cap
$301.46M
Enterprise Value$290.85M
Total Cash (Recent Filing)$245.89M
Total Debt (Recent Filing)$39.58M
Price to Earnings (P/E)―
Beta3.28
Next Earnings
May 13, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding70,931,015
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.77
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-694.16
Enterprise Value/Ebitda-2.14
Forecast
1Y Price Target
$8.25Price Target Upside485.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Launch PreparednessInitiation of pre-commercial activities, including scaling manufacturing and advancing a companion diagnostic, positions the program for launch readiness if regulatory approval is obtained.
Dose-selection And Investor SentimentAnalyst recommends accumulating shares because dose-selection enrollment is complete and the study design supports a potential accelerated approval, boosting investor confidence.
Regulatory PathwayRegulatory alignment on a randomized confirmatory Phase 3 design supports a clearer path toward potential approval and reduces regulatory uncertainty around the program.
Bears Say
Diagnostic Integration RiskUncertainty whether the Cyclin E1 immunohistochemistry diagnostic can be adopted in routine clinical practice creates execution risk for identifying and capturing the intended patient population.
Dose Efficacy Durability RiskKey uncertainty remains about whether a higher dose will deliver greater or more durable benefit across an expanded patient group, raising the risk that registrational studies may not meet efficacy expectations.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.13 and its highest was $6.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $301.46M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 14 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.427 by -$0.073.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.5.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 70,931,015 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.427. Following the earnings report the stock price went down -21.348%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.25 (485.11% Upside)
$8.25 (485.11% Upside)
Hedge Fund Trend
Decreased
By 14.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $116.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
-52.77%
Trailing 12-Months
Asset Growth
-32.85%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector, leveraging its expertise in medicinal chemistry and translational science to develop drug candidates aimed at improving patient outcomes in oncology. Zentalis' core products include a pipeline of proprietary agents designed to address unmet medical needs in cancer treatment.
ZNTL Stock 12 Month Forecast
Average Price Target
$8.25
▲(485.11% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
30.04% Insiders
5.82% Mutual Funds
0.01% Other Institutional Investors
59.73% Public Companies and
Individual Investors